INTRODUCTION: Atypical small acinar proliferation (ASAP) and high grade prostatic intraepithelial neoplasia (HGPIN) are considered precancerous. We aimed to measure the rate of repeat biopsy and adenocarcinoma in patients with ASAP and HGPIN and identify any clinico-pathologic parameters at diagnosis of ASAP/HGPIN that are predictive of adenocarcinoma. MATERIALS AND METHODS: Patients with a diagnosis of ASAP/HGPIN with no previous or concomitant cancer were identified. Prostate specific antigen (PSA) and magnetic resonance imaging (MRI) changes were monitored. Re-biopsy was at clinician discretion. RESULTS: Nineteen were diagnosed with ASAP and 17 with HGPIN. Seven with ASAP (37%) and 6 with HGPIN (35%) underwent re-biopsy. Three (16%) with ASAP and 5 with HGPIN (29%) were diagnosed with adenocarcinoma. The difference in cancer detection rates between ASAP and HGPIN was not significant (p = 0.35). Five (14%) in total required definitive therapy for adenocarcinoma. Twenty-three (64%) did not undergo repeat biopsy. Parameters at diagnosis of HGPIN and ASAP, including PSA, prostate volume and PSA density, were compared between the cancer and non-cancer cohorts with none found to be predictive of adenocarcinoma. CONCLUSION: By monitoring PSA and MRI changes, we managed to spare re-biopsy in two-thirds of patients. Further evaluation is necessary to characterize a surveillance protocol in these populations.
INTRODUCTION: Atypical small acinar proliferation (ASAP) and high grade prostatic intraepithelial neoplasia (HGPIN) are considered precancerous. We aimed to measure the rate of repeat biopsy and adenocarcinoma in patients with ASAP and HGPIN and identify any clinico-pathologic parameters at diagnosis of ASAP/HGPIN that are predictive of adenocarcinoma. MATERIALS AND METHODS: Patients with a diagnosis of ASAP/HGPIN with no previous or concomitant cancer were identified. Prostate specific antigen (PSA) and magnetic resonance imaging (MRI) changes were monitored. Re-biopsy was at clinician discretion. RESULTS: Nineteen were diagnosed with ASAP and 17 with HGPIN. Seven with ASAP (37%) and 6 with HGPIN (35%) underwent re-biopsy. Three (16%) with ASAP and 5 with HGPIN (29%) were diagnosed with adenocarcinoma. The difference in cancer detection rates between ASAP and HGPIN was not significant (p = 0.35). Five (14%) in total required definitive therapy for adenocarcinoma. Twenty-three (64%) did not undergo repeat biopsy. Parameters at diagnosis of HGPIN and ASAP, including PSA, prostate volume and PSA density, were compared between the cancer and non-cancer cohorts with none found to be predictive of adenocarcinoma. CONCLUSION: By monitoring PSA and MRI changes, we managed to spare re-biopsy in two-thirds of patients. Further evaluation is necessary to characterize a surveillance protocol in these populations.
Entities:
Keywords:
Atypical small acinar proliferation; High grade prostatic intraepithelial neoplasia; Prostate biopsy; Prostatic adenocarcinoma
Authors: Dima Raskolnikov; Soroush Rais-Bahrami; Arvin K George; Baris Turkbey; Nabeel A Shakir; Chinonyerem Okoro; Jason T Rothwax; Annerleim Walton-Diaz; M Minhaj Siddiqui; Daniel Su; Lambros Stamatakis; Pingkun Yan; Jochen Kruecker; Sheng Xu; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2014-08-20 Impact factor: 7.450
Authors: Rodolfo Montironi; Vincenzo Scattoni; Roberta Mazzucchelli; Antonio Lopez-Beltran; David G Bostwick; Francesco Montorsi Journal: Eur Urol Date: 2006-08-10 Impact factor: 20.096
Authors: Derek W Cool; Cesare Romagnoli; Jonathan I Izawa; Joseph Chin; Lori Gardi; David Tessier; Ashley Mercado; Jonathan Mandel; Aaron D Ward; Aaron Fenster Journal: Can Urol Assoc J Date: 2016 Sep-Oct Impact factor: 1.862
Authors: Paras B Singh; Caroline M Nicholson; Narasimhan Ragavan; Rosemary A Blades; Francis L Martin; Shyam S Matanhelia Journal: BMC Urol Date: 2009-05-27 Impact factor: 2.264
Authors: Andrew Leone; Katherine Rotker; Christi Butler; Anthony Mega; Jianhong Li; Ali Amin; Stephen F Schiff; Gyan Pareek; Dragan Golijanin; Joseph F Renzulli Journal: Prostate Cancer Date: 2015-09-14
Authors: Borna K Barth; Niels J Rupp; Alexander Cornelius; Daniel Nanz; Rainer Grobholz; Martin Schmidtpeter; Peter J Wild; Daniel Eberli; Olivio F Donati Journal: Curr Urol Date: 2019-03-08